123 results on '"Kerr, D."'
Search Results
2. Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population
3. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
4. Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†
5. Research-intensive cancer care in the NHS in the UK
6. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008
7. O-016 A prognostic marker for colorectal cancer: combining analyses of ploidy and stroma
8. Introduction
9. Variation in the availability of cancer drug generics in the United States of America
10. Generic drugs: their role in better value cancer care
11. Cancer in Africa: supporting advocates to stop the runaway train
12. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial
13. Better value cancer care for the 21st century
14. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
15. Chronic non-communicable diseases, the European Chronic Disease Alliance—and cancer
16. ESMOʼs new strategic plan: our societyʼs road to the future of oncology
17. What is the role and impact of molecular markers on treatment decisions in the adjuvant setting of colorectal cancer?
18. Need for global action for cancer control
19. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007
20. New wave
21. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan
22. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006
23. Now the New Year reviving old desires
24. Do we bear any moral responsibility for improving cancer care in Africa?
25. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study
26. Concordia res parvae crescent
27. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer
28. Teenage kicks
29. Signal transduction blockade and cancer: combination therapy or multi-targeted inhibitors?
30. The Entente Cordiale—natural and necessary
31. Can we individualise chemotherapy for colorectal cancer?
32. A little citadel of light in a malignant sea of darkness
33. Europeʼs eye is fixed on mighty things
34. Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors
35. Pride and judgment: the Annals of Oncology prizes
36. Per ardua ad astra
37. The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy
38. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin
39. Hepatocellular carcinoma
40. Two cultures or two faces?
41. A national cancer plan for the UK
42. A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: Correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints
43. Cancer-related fatigue: Inevitable, unimportant and untreatable? Results of a multi-centre patient survey
44. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: Non-randomised comparison of weekly versus four-weekly schedules - less pain, same gain
45. World summit against cancer for the new millennium: The Charter of Paris
46. 'Old Kerr's Almanac'
47. ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: results of a prospective single centre clinical utility study (PRECISE STUDY)
48. Hand-foot syndrome is a biomarker of improved survival following treatment with capecitabine
49. An evaluation of the clinical utility of a panel of variants in DPYD and ENOSF1 for predicting common capecitabine related toxicities
50. Improving treatment decisions in colon cancer: The tumor-stroma ratio (TSR) additional to the TNM classification
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.